REPORT FROM THE 13TH CONGRESS OF THE EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES (EFNS), FLORENCE, ITALY, SEPTEMBER 12-15, 2009 – A 33-week comparison of extended-release (once-daily) and immediate-release (TID) pramipexole reports that the two formulations are comparable in patients with early Parkinsons disease (Poewe et al. EFNS 2009). A total of 539 patients were randomized to pramipexole ER, pramipexole IR or placebo. Doses were titrated up to 4.5 mg/day followed by maintenance at the optimized dose. Levodopa was permitted as a rescue medication.